AMO Pharma Limited, a US-based privately held biopharmaceutical company announced on Tuesday that it has completed enrolment of patients in the REACH-CDM study of the investigational therapy AMO-02 to treat congenital myotonic dystrophy.

The REACH-CDM pivotal trial, a double-blind, placebo-controlled, randomised study, is conducted in children and adolescents with congenital-onset myotonic dystrophy aimed at supporting a future submission for marketing authorisation in congenital myotonic dystrophy.

Dr Joseph Horrigan, chief medical officer at AMO Pharma, said, 'Completion of enrolment represents a significant milestone for both AMO Pharma and the patients and families affected by congenital myotonic dystrophy around the world. We are very grateful to the patients, caregivers and leaders from the CDM advocacy community who have helped build awareness of this study and to the outstanding team of investigators who are dedicated to advancing this historic research effort and bringing a new disease-modifying therapy to CDM patients.'